Evert B. Schimmelpennink

CIK: 0001713795

Transaction Breakdown

Open Market Buys (P)1 (12.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (12.5%)

Derivative conversions

Awards (A)6 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

CTNM

Contineum Therapeutics, Inc.

Director

LENZ

LENZ Therapeutics, Inc.

DirectorOfficer

IBIO

iBio, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

CTNM
Contineum Therapeutics, Inc.
Jun 26, 2026
Award(A)
Stock Option (right to buy)
Direct
19K shares-
LENZ
LENZ Therapeutics, Inc.
Mar 27, 2026
Purchase(P)
Direct
28.1K shares at avg. $8.95$251K
LENZ
LENZ Therapeutics, Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
358.1K shares-
IBIO
iBio, Inc.
Nov 20, 2025
Award(A)
Stock Option (right to buy)
Direct
13.5K shares-
CTNM
Contineum Therapeutics, Inc.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
14.8K shares-
LENZ
LENZ Therapeutics, Inc.
Mar 7, 2025
Exercise(M)
Direct
4.2K shares at avg. $1.04$4K
LENZ
LENZ Therapeutics, Inc.
Jan 9, 2025
Award(A)
Stock Option (right to buy)
Direct
279.1K shares-
IBIO
iBio, Inc.
Nov 21, 2024
Award(A)
Stock Option (right to buy)
Direct
18.9K shares-

		Type	Shares	Price		Ownership
Jun 26, 2026	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	19,000	-	-	Direct
Mar 27, 2026	LENZ LENZ Therapeutics, Inc.	Purchase(P)	28,089	$8.95	$251,411	Direct
Jan 2, 2026	LENZ LENZ Therapeutics, Inc.	Award(A) Stock Option (right to buy)	358,100	-	-	Direct
Nov 20, 2025	IBIO iBio, Inc.	Award(A) Stock Option (right to buy)	13,500	-	-	Direct
Jun 26, 2025	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	14,750	-	-	Direct
Mar 7, 2025	LENZ LENZ Therapeutics, Inc.	Exercise(M)	4,200	$1.04	$4,368	Direct
Jan 9, 2025	LENZ LENZ Therapeutics, Inc.	Award(A) Stock Option (right to buy)	279,100	-	-	Direct
Nov 21, 2024	IBIO iBio, Inc.	Award(A) Stock Option (right to buy)	18,900	-	-	Direct

1-8 of 8 transactions

About Schimmelpennink Evert B.

Schimmelpennink Evert B. (SEC CIK 0001713795) files insider reports with the SEC as Director of Contineum Therapeutics, Inc. (CTNM), President, CEO and Secretary of LENZ Therapeutics, Inc. (LENZ) and Director of iBio, Inc. (IBIO).

Signal8 holds 8 ownership filings by Schimmelpennink Evert B., all Form 4s, filed between Nov 25, 2024 and Jun 26, 2026. Those filings report 8 transactions, from Nov 21, 2024 to Jun 26, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Schimmelpennink Evert B.'s filings is in SAN DIEGO, CA.

Recent filings by Schimmelpennink Evert B.

Jun 26, 2026: Grant or award of CTNM derivative securities (Form 4, code A).
Mar 27, 2026: Open-market purchase of LENZ shares (Form 4, code P).
Jan 2, 2026: Grant or award of LENZ derivative securities (Form 4, code A).
Nov 20, 2025: Grant or award of IBIO derivative securities (Form 4, code A).
Jun 26, 2025: Grant or award of CTNM derivative securities (Form 4, code A).

Other insiders filing for Contineum Therapeutics, Inc. (CTNM)

Stengone Carmine N., CEO and President
Lorrain Daniel S., Chief Scientific Officer
Watkins Tim, CMO & Head of Development
Miralles Gines Diego, Director
Lyons-Williams Lori, Director
Ware Olivia C, Director

How to read Form 4 transaction codes